Biosimilars 20/20: A Market Analysis of the Growth and Implications of Biosimilars Over the Next Five Years

TAMPA, FL, March 16, 2015 — The biosimilars event of the year – Biosimilars 20/20 – is scheduled for June 3-4, 2015 at The Hub in Philadelphia, PA. The event promises to provide an in-depth look into the future of the biosimilars market and address challenges of implementation.

Biosimilars 20/20 will also outline key opportunities expected to emerge during biosimilars’ first five years of market entry in the United States, as well as analyze trends seen in Europe. With the US Food and Drug Administration’s (FDA) first approval of a biosimilar product, there is no better time to discuss the future, growth, and implications with leading companies and executives in the industry.

“After nearly a decade of intense regulatory scrutiny, growth and investment in biosimilars is accelerating, creating a need for regular, updated information and assessments,” said Gary M. Cohen, BSPharm, RPh, CSP, Publisher, Specialty Pharma Journal (SPJ). “Biosimilars 20/20’s comprehensive assessment will provide attendees with the latest information for strategic investment and decision-making in this growing sector.”

The two-day event will open with a session featuring an analysis of the current biosimilars pipeline and implications for the specialty pharmacy industry over the next five years. The pipeline presentation, which examines the expected sequence of biosimilar approval and implications for parent drugs, will set the stage for the event, designed to deliver five-year projections for this rapidly evolving industry.

Additional sessions will address perspectives from physicians and payers, the value and means of patient education, interchangeability, legal/regulatory aspects, biosimilars in the market, R&D, health information technology (HIT), and its impact on biosimilars and more.

For more information on the Biosimilars 20/20 Conference, visit biosimilars.specialtycme.org.

Check Also

Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded

SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and …

Leave a Reply

Your email address will not be published. Required fields are marked *